VistaGen Therapeutics's Total Assets for the quarter that ended in Mar. 2022 was $74.64 Mil.
During the past 12 months, VistaGen Therapeutics's average Total Assets Growth Rate was 25.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 92.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 64.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 44.20% per year.
During the past 13 years, VistaGen Therapeutics's highest 3-Year average Total Assets Growth Rate was 539.10%. The lowest was -8.50%. And the median was 65.10%.
Total Assets is connected with ROA %. VistaGen Therapeutics's annualizedROA % for the quarter that ended in Mar. 2022 was -80.82%. Total Assets is also linked to Revenue through Asset Turnover. VistaGen Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 was 0.00.
VistaGen Therapeutics Total Assets Historical Data
The historical data trend for VistaGen Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Total Assets
11.28
14.01
5.77
108.28
74.64
VistaGen Therapeutics Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Total Assets
108.28
103.91
100.50
90.54
74.64
VistaGen Therapeutics Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
VistaGen Therapeutics's Total Assets for the fiscal year that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics (NAS:VTGN) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
VistaGen Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
VistaGen Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.02(1.7%) Volume: 591,921 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
